Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Multiple-dose versus single-dose cefazolin for infection prevention after revision arthroplasty
2019-002438-35Phase 4Completed
- Sponsor
- Radboudumc
- Start
- Jun 2019
- Modality
- Reversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of cefazolin in periprosthetic joint infection (PJI) and surgical site infection (SSI) (2 arms), sponsored by Radboudumc. Primary endpoint: Infection-free implant survival at 1 year. Started Jun 2019; status: completed.
02
Drugs
cefazolin
03
Conditions
periprosthetic joint infection (PJI)surgical site infection (SSI)
Beyond the preview
Go deeper on 2019-002438-35.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2019-002438-35.